{"filings":[{"id":483276,"accession_number":"0001193125-26-228013","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2026-05-18T13:04:56+00:00","items":["1.01","2.03","2.01","7.01","9.01"],"status":"ready","headline":"Neurocrine completes $2.9B acquisition of Soleno Therapeutics, adds VYKAT XR for Prader-Willi","event_type":"m_and_a","confidence":"high","bullets":["Tender offer accepted 46.4M shares (88.9% of Soleno) at $53/sh cash; total equity value ~$2.9B.","Merger completed May 18, 2026; Soleno becomes wholly owned subsidiary; shares to be delisted from Nasdaq.","VYKAT XR (diazoxide choline) is first approved therapy for hyperphagia in Prader-Willi syndrome (ages 4+).","Entered $1.0B senior secured revolving credit facility (5-yr); initial $600M drawn; SOFR + 1.125%-1.75% margin."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99724,"accession_number":"0000914475-26-000025","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Biosciences reports Q1 2026 sales $811M (up 44%); agrees to acquire Soleno Therapeutics for $2.9B","event_type":"earnings","confidence":"high","bullets":["Net product sales of $811.0M in Q1 2026, a 44% increase year-over-year, led by INGREZZA ($656.9M) and CRENESSITY ($153.3M).","Definitive agreement to acquire Soleno Therapeutics for $53.00 per share ($2.9B equity value), expected to close in Q2 2026.","Initiated Phase 2 study of NBI-1117570 (dual M1/M4 agonist) for schizophrenia and Phase 1 study of NBIP-’2118 (CRF2 agonist) for obesity.","Reaffirmed full-year 2026 INGREZZA net sales guidance of $2.7-$2.8 billion and total cash of $2.65 billion at March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":1.91,"consensus_revenue_estimate":null,"consensus_revenue_actual":814500000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99723,"accession_number":"0001193125-26-142904","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2026-04-06T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Neurocrine to acquire Soleno Therapeutics for $53.00 per share in cash","event_type":"m_and_a","confidence":"high","bullets":["Tender offer for all Soleno shares at $53.00 cash each; no financing condition.","Offer requires >50% shares tendered, HSR clearance, no material adverse effect.","Termination fees: Soleno pays $95.25M for superior proposal; Neurocrine pays $141.5M for antitrust failure.","Soleno board recommends tender; CEO and former CFO (1.01% combined) signed support agreements.","Deal structured as tender offer followed by merger under Section 251(h) of DGCL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115891,"accession_number":"0000914475-26-000006","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2026-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine reports Q4 2025 revenue $805.5M, EPS $1.48 GAAP; guides INGREZZA 2026 sales $2.7-2.8B","event_type":"earnings","confidence":"high","bullets":["Q4 total net product sales $798.3M (+29% YoY); full year $2.83B (+22% YoY).","INGREZZA Q4 sales $657.5M (+7% YoY); full year $2.51B (+9% YoY); 2026 guidance $2.7-2.8B.","CRENESSITY Q4 sales $135.3M (vs $1.7M YoY); full year $301.2M; 2,048 new patient start forms in FY.","GAAP diluted EPS Q4 $1.48 (vs $1.00); full year $4.67 (vs $3.29). Non-GAAP EPS Q4 $1.88 (vs $1.69).","Cash & marketable securities $2.54B at Dec 31, 2025; R&D and SG&A guidance provided for 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":4.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":2860500000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132302,"accession_number":"0000914475-25-000186","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-11-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Neurocrine extends former CMO Eiry Roberts as Strategic Advisor through Dec 31, 2026","event_type":"leadership","confidence":"high","bullets":["Roberts, former CMO, transitioned to Strategic Advisor effective June 2, 2025; term extended to Dec 31, 2026 (Amended Employment Agreement).","Base salary of $731,400 through Dec 31, 2025; future salary to be set by Compensation Committee thereafter.","Annual cash incentive bonus target 60% of base pay for 2025 and 2026, subject to corporate and individual goals.","Employment agreement expires Dec 31, 2026 unless earlier terminated; no severance upon natural expiration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":132301,"accession_number":"0000914475-25-000180","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Q3 net product sales $790M (+28% YoY); INGREZZA $687M (+12%); CRENESSITY $98M","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $2.04 (diluted) vs $1.24 YoY; Non-GAAP EPS $2.17 vs $1.81; net income $209.5M.","INGREZZA net sales $686.6M (+12% YoY) driven by record quarterly new and total prescriptions.","CRENESSITY launch generated $98.1M net sales with 540 new patient enrollment start forms.","FY2025 INGREZZA guidance reaffirmed at $2.50-2.55B; GAAP R&D $1.00-1.02B, SG&A $1.14-1.16B.","Initiated second Phase 3 trial for direclidine (schizophrenia); osavampator Phase 3 in MDD enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":3.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":2055000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148884,"accession_number":"0000914475-25-000157","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Neurocrine Biosciences Q2 2025: Revenue $687.5M up 16.5% YoY; valbenazine Phase 3 schizophrenia miss","event_type":"earnings","confidence":"high","bullets":["Total revenue $687.5M; INGREZZA $624.4M (+8% YoY), CRENESSITY $53.2M (launch year).","GAAP diluted EPS $1.06 (vs $0.63 Q2 2024); Non-GAAP diluted EPS $1.65 (vs $1.63).","INGREZZA 2025 net product sales guidance narrowed to $2.50-2.55B from $2.50-2.60B.","CRENESSITY: 664 new patient enrollment start forms in Q2; 76% reimbursement coverage for dispensed scripts.","Phase 3 study of valbenazine for adjunctive schizophrenia did not meet primary endpoint; safety consistent."],"consensus_eps_estimate":null,"consensus_eps_actual":1.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":1260100000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167788,"accession_number":"0000914475-25-000139","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Neurocrine CMO Eiry Roberts to step down; Sanjay Keswani named successor June 2, 2025","event_type":"leadership","confidence":"high","bullets":["Dr. Eiry Roberts transitions from CMO to Strategic Advisor to the CEO, effective June 2, 2025 through Dec 31, 2025.","Dr. Sanjay Keswani will succeed Dr. Roberts as Chief Medical Officer, effective June 2, 2025.","Dr. Roberts receives annual base salary of $731,400 and target bonus of 60% of base pay in new advisory role.","Outstanding equity awards continue vesting; severance terms substantially unchanged from prior agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167787,"accession_number":"0000914475-25-000120","cik":914475,"company_name":"NEUROCRINE BIOSCIENCES INC","ticker":"NBIX","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["5.02","5.07"],"status":"ready","headline":"Neurocrine holds 2025 annual meeting; shareholders approve new equity plan and amended ESPP","event_type":"other","confidence":"high","bullets":["Four Class II directors elected for three-year terms expiring 2028: Kyle Gano, Richard Pops, Shalini Sharp, Stephen Sherwin (each >72M votes).","Advisory say-on-pay approved: ~78M for, ~6M against, ~1.7M abstentions.","2025 Equity Incentive Plan approved: ~72.6M for, ~12.9M against.","Amended and Restated 2018 ESPP approved: ~85.4M for, ~138K against.","Ratification of Ernst & Young as independent auditor for FY2025 approved: ~85M for, ~5.2M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}